Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02729753 · ClinicalTrials.gov registry record · NA

Clinical Study to Evaluate CryoBalloon™ Full and Swipe Ablation Systems for Ablation of Human Esophageal Epithelium

A NA study of Esophageal Cancer, sponsored by Pentax Medical.

Completed
Registry status
NA
Development phase
10
Enrollment target
2
Study locations

NCT02729753: Completed NA study of Esophageal Cancer, sponsored by Pentax Medical.

NCT02729753 is a NA study of Esophageal Cancer that has completed, run by Pentax Medical. The registered enrollment target is 10 participants, below the 499-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02729753, a NA study of Esophageal Cancer, has completed, sponsored by Pentax Medical.

COMPLETED
Registry status
NA
Development phase
10 participants
Enrollment target
2
Study locations

Study Summary

This study will evaluate the C2 CryoBalloon™ Full and Swipe Ablation Systems for the ablation of human esophageal epithelium in patients scheduled to undergo esophagectomy for reasons unrelated to the objective of the study

Primary Outcome

Number of participants with serious, device-related adverse events after treatment with the CryoBalloon™ Swipe Ablation System

Conditions Studied

Interventions

  • DEVICE CryoBalloon™ Full Ablation System
  • DEVICE CryoBalloon™ Swipe Ablation System

Study Locations (2)

Texas

  • MD Anderson Cancer Center - Houston

Washington

  • Swedish Medical Center and Cancer Institute - Seattle

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2016-04
Est. Completion 2016-10-30
Phase NA
Pentax Medical

4 total trials

What the finished NCT02729753 record still lists

NCT02729753 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 499-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Esophageal Cancer appearing as the primary indexed condition, and to 2 interventions - of which CryoBalloon™ Full Ablation System is the first listed.

NCT02729753 reports a single indexed study location in Texas, Washington.

Frequently Asked Questions

What is clinical trial NCT02729753 about?

NCT02729753 is a clinical study titled "Clinical Study to Evaluate CryoBalloon™ Full and Swipe Ablation Systems for Ablation of Human Esophageal Epithelium". This study will evaluate the C2 CryoBalloon™ Full and Swipe Ablation Systems for the ablation of human esophageal epithelium in patients scheduled to undergo esophagectomy for reasons unrelated to the objective of the study

What is the current status of trial NCT02729753?

This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2016-04. Estimated completion is 2016-10-30.

What conditions does trial NCT02729753 study?

This clinical trial studies the following conditions: Esophageal Cancer.

What interventions are being tested in trial NCT02729753?

The interventions under investigation include: CryoBalloon™ Full Ablation System (DEVICE), CryoBalloon™ Swipe Ablation System (DEVICE).

Who is sponsoring clinical trial NCT02729753?

This trial is sponsored by Pentax Medical, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02729753 being conducted?

This trial has 2 study locations across Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Esophageal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02729753's enrollment target sits among peer trials

10 121st of 123 higher than 2 of 123 other Esophageal Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Esophageal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00623389 · 10 participants · NA

    Evaluation of an Advanced Lower Extremity Neuroprostheses

  • NCT01241864 · 10 participants · Phase 2

    Islet Transplantation in Type 1 Diabetic Kidney Allograft

  • NCT01293214 · 10 participants · NA

    Vascularized Composite Allotransplantation for Multiple Extremity Amputations

  • NCT01474148 · 10 participants · NA

    A Neuroprosthesis for Seated Posture and Balance

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02729753, the US trial registry maintained by the National Library of Medicine. NCT02729753 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.